Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MCRB

MCRB - Seres Therapeutics Inc Stock Price, Fair Value and News

$15.09-0.35 (-2.27%)
Market Closed

74/100

MCRB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

74/100

MCRB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$22.53

Target 3M

$16.65

Target 6M

$18.42

MCRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MCRB Price Action

Last 7 days

0.3%

Last 30 days

1.1%

Last 90 days

-4.4%

Trailing 12 Months

-7.3%

MCRB RSI Chart

MCRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MCRB Valuation

Market Cap

136.5M

Price/Earnings (Trailing)

25.31

Price/Sales (Trailing)

0.9

Price/Free Cashflow

-5.84

MCRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$22.53

Target 3M

$16.65

Target 6M

$18.42

MCRB Fundamentals

MCRB Revenue

Revenue (TTM)

127.8M

Rev. Growth (Yr)

189.13%

Rev. Growth (Qtr)

19.55%

MCRB Earnings

Earnings (TTM)

5.4M

Earnings Growth (Yr)

-90.76%

Earnings Growth (Qtr)

141.32%

MCRB Profitability

Return on Equity

12.34%

Return on Assets

3.76%

Free Cashflow Yield

-17.12%

MCRB Investor Care

Shares Dilution (1Y)

5.97%

Diluted EPS (TTM)

0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20230132.1M131.2M127.8M
2022110.5M76.0M41.6M7.1M
202126.1M30.0M155.3M144.9M
202035.4M28.9M23.3M33.2M
201931.6M39.5M37.5M34.5M
201833.1M34.7M20.7M28.3M
201722.1M22.1M32.1M32.1M
20165.9M11.2M16.5M21.8M
2015000638.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Seres Therapeutics Inc

MCRB
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEserestherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES431

Seres Therapeutics Inc Frequently Asked Questions

MCRB is the stock ticker symbol of Seres Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Seres Therapeutics Inc is 136.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MCRB's fair value in chart for subscribers.

The fair value guage provides a quick view whether MCRB is over valued or under valued. Whether Seres Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seres Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MCRB.

As of Wed Jan 28 2026, MCRB's PE ratio (Price to Earnings) is 25.31 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MCRB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Seres Therapeutics Inc has provided -0.301 (multiply by 100 for percentage) rate of return.